Sen. Sanders launches probe of Novo’s Wegovy and Ozempic pricing

Sen. Bernie Sanders (I-VT) is ramp­ing up his cam­paign against what he says are “out­ra­geous­ly high” list prices for No­vo Nordisk’s weight loss and di­a­betes block­busters We­govy and Ozem­pic.

The sen­a­tor an­nounced Wednes­day that his Com­mit­tee on Health, Ed­u­ca­tion, La­bor and Pen­sions (HELP) is launch­ing an in­ves­ti­ga­tion in­to No­vo’s pric­ing strat­e­gy, not­ing that We­govy and Ozem­pic are hun­dreds of dol­lars cheap­er in oth­er coun­tries. Sanders said in a let­ter to No­vo Nordisk CEO Lars Fruer­gaard Jør­gensen that high costs keep the drugs out of reach for some pa­tients, and threat­en to “bank­rupt Medicare, Med­ic­aid, and our en­tire health care sys­tem.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.